Ken Griffin Caribou Biosciences, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$1.62 - $5.05 $77,760 - $242,400	48,000 Added 214.29%	70,400 $115,000
Q1 2024 May 15, 2024	BUY	$4.82 - $8.26 $96,400 - $165,200	20,000 Added 833.33%	22,400 $115,000
Q4 2023 Feb 14, 2024	SELL	$3.58 - $6.25 $24,702 - $43,125	-6,900 Reduced 74.19%	2,400 $13,000
Q3 2023 Nov 14, 2023	SELL	$4.08 - $8.14 $46,512 - $92,796	-11,400 Reduced 55.07%	9,300 $44,000
Q2 2023 Aug 14, 2023	BUY	$4.04 - $5.47 $6,464 - $8,752	1,600 Added 8.38%	20,700 $87,000
Q1 2023 May 15, 2023	BUY	$4.3 - $7.78 $52,890 - $95,694	12,300 Added 180.88%	19,100 $101,000
Q4 2022 Feb 14, 2023	BUY	$5.57 - $11.01 $37,876 - $74,868	6,800 New	6,800 $42,000

140

52.6M

32.5K

89.8K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $170M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.